🎉 M&A multiples are live!
Check it out!

Context Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Context Therapeutics and similar public comparables like Galapagos, Pharming, and Benevolent AI.

Context Therapeutics Overview

About Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.


Founded

2015

HQ

United States of America
Employees

5

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$31.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Context Therapeutics Financials

Context Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Context Therapeutics achieved revenue of n/a and an EBITDA of -$25.1M.

Context Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Context Therapeutics valuation multiples based on analyst estimates

Context Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$25.1M n/a XXX XXX XXX
EBITDA Margin -Infinity% NaN% XXX XXX XXX
Net Profit -$10.5M -$14.8M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Context Therapeutics Stock Performance

As of March 14, 2025, Context Therapeutics's stock price is $1.

Context Therapeutics has current market cap of $52.9M, and EV of -$31.6M.

See Context Therapeutics trading valuation data

Context Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$31.6M $52.9M XXX XXX XXX XXX $-0.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Context Therapeutics Valuation Multiples

As of March 14, 2025, Context Therapeutics has market cap of $52.9M and EV of -$31.6M.

Context Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Context Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Context Therapeutics and 10K+ public comps

Context Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$31.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -1.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Context Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Context Therapeutics Valuation Multiples

Context Therapeutics's NTM/LTM revenue growth is Infinity%

Context Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $5.0M for the same period.

Over next 12 months, Context Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Context Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Context Therapeutics and other 10K+ public comps

Context Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $5.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Context Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Context Therapeutics M&A and Investment Activity

Context Therapeutics acquired  XXX companies to date.

Last acquisition by Context Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Context Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Context Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Context Therapeutics

When was Context Therapeutics founded? Context Therapeutics was founded in 2015.
Where is Context Therapeutics headquartered? Context Therapeutics is headquartered in United States of America.
How many employees does Context Therapeutics have? As of today, Context Therapeutics has 5 employees.
Who is the CEO of Context Therapeutics? Context Therapeutics's CEO is Mr. Martin A. Lehr.
Is Context Therapeutics publicy listed? Yes, Context Therapeutics is a public company listed on NAS.
What is the stock symbol of Context Therapeutics? Context Therapeutics trades under CNTX ticker.
When did Context Therapeutics go public? Context Therapeutics went public in 2021.
Who are competitors of Context Therapeutics? Similar companies to Context Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Context Therapeutics? Context Therapeutics's current market cap is $52.9M
Is Context Therapeutics profitable? Yes, Context Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.